• Home
  • Company Profile
  • News
  • Products
  • Cart
  • Checkout
  • My Account
  • Terms & Conditions
  • Privacy Policy
Paragon BioTeck, Inc.Paragon BioTeck, Inc.
  • HOME
  • ABOUT
    • Company Profile
    • Business Integrity
  • PRODUCTS
    • Diagnostics
      • Phenylephrine Hydrochloride Ophthalmic Solution USP 2.5% 15 mL
      • Phenylephrine Hydrochloride Ophthalmic Solution USP 2.5% 10mL
      • Phenylephrine Hydrochloride Ophthalmic Solution USP 10% 5mL
  • NEWS
  • CONTACT

Dry Eye article by Paul S. Koch, MD, published in Ophthalmology Times

Home » News » Dry Eye article by Paul S. Koch, MD, published in Ophthalmology Times

Dry Eye article by Paul S. Koch, MD, published in Ophthalmology Times

05/05/2016 Punctal Occlusion

Article discusses the importance of diagnosis, treatment, and patient communication in the treatment of dry eye disease

An April 15, 2016 Ophthalmology Times article by Paul S. Koch, MD, “3 steps to improve ocular health of dry eye patients,” provides an overview of the current diagnostic, treatment, and communication strategies for clinicians treating patients with dry eye disease. Dr. Koch notes that contemporary physicians have a wide array of tools at their disposal to treat dry eye, which, if implemented correctly, can lead to greater overall patient satisfaction.

 

Dr. Koch identifies comprehensive patient history and tear osmolarity testing to be two of the most important diagnostic tools relating to dry eye disease. After a patient’s osmolarity has been determined, there are a variety of treatment options available for those with dry eye symptoms. Dr. Koch begins with two topical drop medications; if these fail to provide sufficient relief, temporary punctum plugs, such as the Comfortear® Lacrisolve™ 180 Absorbable Punctum Plugs, are inserted. Punctum plugs may provide relief to dry eye sufferers and are also an important preoperative tool used to optimize tear film stability and enhance postoperative outcomes. If neither topical drops nor punctal plugs resolve the patient’s dry eye symptoms, then an agent such as cyclosporine ophthalmic emulsion or one containing omega fatty acids is attempted to stimulate gland production.

 

Finally, Dr. Koch recommends maintaining clear, comprehensible communication with the patient throughout the diagnostic and treatment process. In conjunction with improved diagnostic tools and a wider array of treatment options, establishing good patient communication facilitates more efficient—and more effective—treatment.

 

To read the full article, visit Ophthalmology Times.

 

Paul S. Koch, MD, is chief surgeon at Koch Eye Associates and serves as chief medical officer of Claris Vision. 

 

Paragon BioTeck, Inc., has developed a line of absorbable and non-absorbable punctum plugs to provide occlusion therapy to treat symptoms associated with dry eye disease that may result from allergies, cataracts, or contact lens intolerance. Patients who are unsure about whether occlusion therapy is right for them should talk with their eye doctor.

Share
0

You also might be interested in

Paragon BioTeck, Inc. Announces Call for 2018 Koch Kellan Scholarship Applicants

Oct 2, 2017

The Koch Kellan Scholarship honors a graduate medical student pursuing[...]

Xinxin Zhang shares her experience at ASCRS•ASOS

Jun 12, 2017

2017 Koch Kellan Scholar, Xinxin Zhang, was formally presented with her scholarship award at a ceremony held on Sunday, May 7. Ms. Zhang was invited to attend the 2017 ASCRS•ASOS annual meeting in Los Angeles on behalf of Paragon BioTeck where she had the opportunity to explore the conference and meet ophthalmic industry leaders. Read on to hear her thoughts about the conference and ceremony.

5 Questions: 2017 Koch Kellan Scholar Xinxin Zhang

May 23, 2017

Each year, Paragon Gives, a Paragon BioTeck initiative, awards the Koch Kellan Scholarship to a third-year ophthalmology student. The scholarship, named for two pillars of the eye care industry — Paul Koch, MD, and Robert Kellan, MD — highlights rising stars who share our dedication to underserved medical needs. This year, we are proud to introduce our 2017 Koch Kellan Scholar: Xinxin Zhang. We caught up with her after the announcement to learn more about her exciting work and future plans.

RECENT POSTS

  • Paragon BioTeck Reformulated FRESHKOTE®, Prompting Eyevance Acquisition 09/14/2018
  • Paragon BioTeck, Inc. Hosts Pearl Buck Preschool Holiday Event 12/01/2017
  • Paragon BioTeck, Inc. Announces Call for 2018 Koch Kellan Scholarship Applicants 10/02/2017
  • Talking to Patients About Eye Health 08/24/2017
  • Xinxin Zhang shares her experience at ASCRS•ASOS 06/12/2017

Newsletter Sign-Up

  • This field is for validation purposes and should be left unchanged.

HOME

Contact Us
News

PRODUCTS

Diagnostics

ABOUT

Company Profile
Business Integrity

CUSTOMER SERVICE

1-888-424-1192
customercare@paragonbioteck.com

© 2017 Paragon BioTeck, Inc. All Rights Reserved.

Privacy Policy | Return Policy | Terms of Use | Social Media Guidelines


Prev Next